YAMASHITA, Y.; HORI, Y.; KOSAKO, H.; OIWA, T.; WARIGAYA, K.; MUSHINO, T.; MURATA, S.; FUJIMOTO, M.; NISHIKAWA, A.; MURATA, S.- ICHI; SONOKI, T.; TAMURA, S. Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with <em>RUNX3</em&gt; overexpression. Hematology Reports, v. 12, n. 1, 15 May 2020.